Medication Guide App

Clinical Trial News

This section provides information about recently completed clinical trials. If you cannot find information about a particular clinical trial, you should note that results may not be available even after the trial ends. Some trials end before completion and results are never published.

Get news by email or subscribe to our news feeds.

MediciNova Announces Positive Interim Safety Data From Clinical Trial of MN-166 (ibudilast) in ALS

Posted 3 days ago in Clinical Trials

LA JOLLA, Calif., April 21, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), announced that Dr. Benjamin Rix Brooks, principal investigator, presented interim safety data from the ongoing clinical trial of MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS) today at the...

Read more...

Onconova Therapeutics, Inc. Submits Pivotal Clinical Trial Protocol for IV Rigosertib in Higher-Risk Myelodysplastic Syndromes to FDA and EMA

Posted 4 days ago in Clinical Trials

NEWTOWN, Pa., April 20, 2015 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that the Company has submitted a protocol for a global pivotal study of IV rigosertib in patients with higher-risk myelodysplastic syndromes (HR-MDS) for whom prior treatment with approved...

Read more...

ARIAD Presents Updated Clinical Data on Brigatinib in Patients with ALK+ Non-Small Cell Lung Cancer

Posted 7 days ago in Clinical Trials

GENEVA & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 17, 2015-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced updated clinical data on its investigational tyrosine kinase inhibitor, brigatinib (AP26113), in patients with anaplastic lymphoma kinase positive (ALK+) advanced non-small cell lung cancer (NSCLC) from an ongoing Phase 1/2 trial. The new results include an analysis of safety and efficacy for...

Read more...

OncoMed Presents Demcizumab Data From Phase 1b Clinical Trial in Non-Small Cell Lung Cancer Patients at the European Lung Cancer Conference

Posted 8 days ago in Clinical Trials

REDWOOD CITY, Calif. and GENEVA, April 16, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (Nasdaq:OMED) presented new data from the Phase 1b clinical trial of demcizumab (anti-DLL4, OMP-21M18) in patients with first-line advanced non-small cell lung cancer (NSCLC) at the European Lung Cancer Conference. Demcizumab is a first-in-class monoclonal antibody targeting DLL4 with anti-cancer stem cell,...

Read more...

Phase III Trial of the Merck and NewLink Genetics Investigational Ebola Vaccine Initiated in Sierra Leone

Posted 10 days ago in Clinical Trials

KENILWORTH, N.J. & AMES, Iowa - April 14, 2015 -- (BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and NewLink Genetics Corporation (NASDAQ: NLNK), confirmed today that the third, late-stage, clinical trial of their Ebola vaccine candidate rVSV-ZEBOV-GP (V920) has been initiated in Sierra Leone. The vaccine candidate was originally developed by the Public Health Agency of...

Read more...

Merck’s Investigational Chronic Hepatitis C Therapy Grazoprevir/Elbasvir Granted FDA Breakthrough Therapy Designations

Posted 2 weeks ago in Clinical Trials

KENILWORTH, N.J.- April 8, 2015 --(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that grazoprevir/elbasvir, an investigational single tablet regimen for the treatment of chronic hepatitis C virus (HCV) infection, has received two new Breakthrough Therapy designations from the U.S. Food and Drug Administration (FDA) for the treatment of patients with chronic...

Read more...

Rhythm Initiates Phase 2b Clinical Trial of Relamorelin for Diabetic Gastroparesis

Posted 2 weeks ago in Clinical Trials

BOSTON and DUBLIN, April 8, 2015 /PRNewswire/ -- Rhythm, a biopharmaceutical company, and Actavis plc (NYSE: ACT), a leading global pharmaceutical company, announced today the initiation of a Phase 2b clinical trial assessing the efficacy and safety of relamorelin (RM-131), Rhythm's ghrelin agonist, for the treatment of gastroparesis in patients with type 1 and type 2 diabetes. Ghrelin is a peptide hormone produced...

Read more...

GlycoMimetics Provides Update on Pfizer's Plans to Initiate Phase 3 Trial with Rivipansel in Mid-2015

Posted 2 weeks ago in Clinical Trials

GAITHERSBURG, Md., April 7, 2015 --(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that Pfizer (NYSE: PFE) has informed the company that it anticipates initiating a planned Phase 3 clinical trial with rivipansel (GMI-1070) in mid-2015. Pfizer has advised GlycoMimetics that the clinical supply issue which has delayed the start of this trial has been discussed with the FDA. Based on these...

Read more...

Capricor Therapeutics Completes Enrollment of Phase II Clinical Trial for Cenderitide to Treat Heart Failure

Posted 3 weeks ago in Clinical Trials

LOS ANGELES, March 31, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (Nasdaq:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that it has completed enrollment of its first Phase II clinical trial of Cenderitide in ambulatory heart failure patients. Cenderitide is in development for the outpatient treatment of patients...

Read more...

Paion Announces Initiation of U.S. Phase III Clinical Trial of Remimazolam for Procedural Sedation During Colonoscopy

Posted 3 weeks ago in Clinical Trials

Aachen, 31 March 2015 – PAION AG, a Specialty Pharma Company today announced the initiation of a U.S. Phase III clinical trial of Remimazolam, an ultra-short-acting sedative/anesthetic, for procedural sedation in patients undergoing colonoscopy. During Phase II clinical trials, Remimazolam displayed faster onset of sedation and greater procedural success compared to midazolam. Remimazolam showed a benign safety...

Read more...

pSivida Corp. Completes Targeted Enrollment of Phase III Trial of Medidur for Posterior Uveitis

Posted 4 weeks ago in Clinical Trials

March 26, 2015 -- WATERTOWN, Mass.--(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV; ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced the completion of the originally targeted enrollment of 120 patients in its pivotal Phase III clinical trial of Medidur™ for the treatment of posterior uveitis, a blinding eye disease. pSivida will permit 10...

Read more...

Conatus Announces Successful Top-Line Results From NAFLD/NASH Clinical Trial of Emricasan

Posted 4 weeks ago in Clinical Trials

SAN DIEGO, March 26, 2015 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced top-line results from the company's Phase 2 double-blind, placebo-controlled clinical trial of emricasan, a first-in-class, orally active pan-caspase protease inhibitor, in 38 patients with nonalcoholic fatty liver disease (NAFLD), including the subset of NAFLD patients with nonalcoholic steatohepatitis (NASH)....

Read more...

Proteon Therapeutics Announces Positive Long-Term Results From Phase 2 Study of Investigational New Drug Vonapanitase

Posted 4 weeks ago in Clinical Trials

DALLAS and WALTHAM, Mass., March 26, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced positive results from a long-term analysis of more than three years of follow-up data from a Phase 2 study of its lead candidate, vonapanitase (formerly PRT-201). The...

Read more...

Tenth Cohort Completed in Cellceutix Clinical Trial of Anti-Cancer Drug Kevetrin, No Adverse Events Reported

Posted 4 weeks ago in Clinical Trials

BEVERLY, MA–(Marketwired – Mar 24, 2015) – Cellceutix Corporation (OTC: CTIX) (the “Company”), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antimicrobial applications, is pleased to announce that the tenth cohort in the Company’s Phase 1 clinical trial of Kevetrin for advanced solid tumors being conducted at Harvard’s Dana-Farber Cancer...

Read more...

Acura Pharmaceuticals Reports Successful Topline Results From Nexafed Extended-Release Clinical Study

Posted 4 weeks ago in Clinical Trials

PALATINE, IL, March 23, 2015 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), today announced preliminary topline results from a pilot clinical study which demonstrated bioequivalence of one formulation of Nexafed (pseudoephedrine HCl) extended-release tablets to Sudafed® 12-Hour Tablets. Nexafed extended-release tablets utilize Acura's IMPEDE 2.0 enhanced methamphetamine-resistant technology. Acura intends to...

Read more...

Pfizer And Lilly Preparing To Resume Phase 3 Chronic Pain Program For Tanezumab

Posted 4 weeks ago in Clinical Trials

Monday, March 23, 2015 -Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) announced today that they are preparing to resume the Phase 3 clinical program for tanezumab. As a result, Pfizer expects to receive a $200 million upfront payment from Lilly in accordance with their collaboration agreement. This announcement follows a decision by the U.S. Food and Drug Administration (FDA) to lift the partial...

Read more...

Boehringer Ingelheim’s Investigational Biologic Cleared Skin Better than Ustekinumab in Head-to-Head Phase II Psoriasis Study

Posted 5 weeks ago in Clinical Trials

SAN FRANCISCO, Calif., March 20, 2015 – For the first time, Boehringer Ingelheim announced Phase II data from its investigational compound BI 655066*. Nearly double the percentage of patients with moderate-to-severe plaque psoriasis achieved clear or almost clear skin (described as PASI 90) after 12 weeks of treatment with BI 655066 compared to ustekinumab (77.1% versus 40% of patients). The study (NCT02054481)...

Read more...

Biogen Idec Presents Positive Interim Results From Phase 1B Study of Investigational Alzheimer’s Disease Treatment Aducanumab

Posted 5 weeks ago in Clinical Trials

CAMBRIDGE, Mass., Friday, March 20, 2015 – Today Biogen Idec (NASDAQ:BIIB) announced data from a pre-specified interim analysis of PRIME, the Phase 1b study of aducanumab (BIIB037), in which aducanumab demonstrated an acceptable safety profile and positive results on radiologic and clinical measurements in patients with prodromal or mild Alzheimer’s disease (AD). These data are being presented today at the 12th...

Read more...

Pfizer Announces Oral Tofacitinib Meets Primary Endpoints In Pivotal Phase 3 Psoriasis Trials

Posted 5 weeks ago in Clinical Trials

Friday, March 20, 2015 - Pfizer Inc. (NYSE:PFE) announced today the presentation of detailed pooled results from two pivotal Phase 3 studies from the Oral treatment Psoriasis Trials (OPT) program at the 73rd American Academy of Dermatology (AAD) Annual Meeting. These results, evaluating the efficacy and safety of tofacitinib citrate for the treatment of adults with moderate to severe chronic plaque psoriasis who are...

Read more...

Phase II Data for Celgene's Investigational Oral GED-0301 for Patients with Active Crohn's Disease Published in NEJM

Posted 5 weeks ago in Clinical Trials

SUMMIT, N.J., Mar 18, 2015 --(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced that results from a double-blind, placebo-controlled, multicenter phase II trial of three doses of GED-0301 (mongersen) in patients with active Crohn's disease were published in the March 19 issue of The New England Journal of Medicine. "GED-0301 offers a unique approach to treating Crohn's, using antisense technology...

Read more...
Older articles
Hide
(web4)